MediWound (MDWD) Tops Q4 EPS by 16c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
MediWound Reports 2016 Fourth Quarter and Full Year Financial Results
February 21, 2017 7:00 AM ESTYAVNE, Israel, Feb. 21, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, reports financial results for the three and 12 months ended December 31, 2016.
Highlights of the fourth quarter of 2016 and recent weeks include:
Revenue for the fourth quarter 2016 of $0.43 million increased 61% compared with revenue of $0.27 million in the prior years fourth quarter, demonstrating continued growth in NexoBrid® sales;Reported final results of the Phase 2 clinical trial of EscharEx® for the... More